Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 12/20 | 0.44 |
| ▸ | CTSS | P25774 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL86237 | 1.00 | CA1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL1654201 | 1.00 | CA1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL25320849 | 0.89 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL25320847 | 0.89 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL4382302 | 0.88 | CA1 (0.46) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL10431195 | 0.86 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL272661 | 0.85 | CA2 (0.53) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL86157 | 0.85 | CA2 (0.53) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL84553 | 0.85 | CA2 (0.53) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL23125479 | 0.84 | CA1 (0.46) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | KEZAR LIFE SCIENCES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20240279238-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2024-08-22 | — | — | US | disclosed |
| CN-112262129-B | Triazacyclododecanesulfonamide (\"TCD\") based protein secretion inhibitors | 科智生命科学公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-3045206-B2 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3045206-B2 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-12-22 | — | — | US | disclosed |
| US-20130172559-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE COMPANY (US) | 2013-07-04 | — | — | US | disclosed |
| US-8410103-B2 | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent | SHIONOGI & CO., LTD. (JP) | 2013-04-02 | — | — | US | disclosed |
| US-8410103-B2 | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent | SHIONOGI & CO., LTD. (JP) | 2013-04-02 | — | — | US | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-20120115875-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | GLAXOSMITHKLINE LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120115875-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | GLAXOSMITHKLINE LLC | 2012-05-10 | — | — | US | disclosed |
| US-8129385-B2 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129385-B2 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | VIIV HEALTHCARE COMPANY | 2009-12-24 | — | — | US | disclosed |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | VIIV HEALTHCARE COMPANY | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | SEC61B, SEC61A1, SEC61G | CA1 3992/4885CA2 3677/4885CA7 3120/4885 |
| US-20120115875-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | CA1 4216/4885CA2 3650/4885CA7 3783/4885 |
| US-20240279238-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | TYMP, CDKN1A, POLL | CA1 4722/4885CA2 3601/4885CA7 3407/4885 |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | CA1 4801/4885CA2 3902/4885CA7 4644/4885 |
| US-20130172559-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | CA1 4216/4885CA2 3650/4885CA7 3783/4885 |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | CA1 3939/4885CA2 3658/4885CA7 3270/4885 |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | NR4A1, NCOA4, NR4A2 | CA1 4216/4885CA2 3650/4885CA7 3783/4885 |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | CD274, CD40, ICOS | CA1 4823/4885CA2 3864/4885CA7 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.